Pain-Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies

Overview

Journal Haemophilia

Specialty Hematology

Date 2024 Dec 18

PMID 39692401

Authors

Cedric Hermans

Mark W Skinner

Brittany Gentile

Elise Lim

Miranda Minhas

Katya Moreno

Eunice Tzeng

Tyler W Buckner

Affiliations

Soon will be listed here.

Abstract

Introduction: People with haemophilia A (PwHA) experience acute and chronic pain associated with reduced quality of life (QoL).

Aims: This post hoc analysis of pooled data from the HAVEN 1 (NCT02622321), 3 (NCT02847637), 4 (NCT03020160) and STASEY (NCT0319179) studies assessed the impact of emicizumab prophylaxis on pain-related QoL in PwHA.

Methods: PwHA received emicizumab during the four studies. In this analysis, pain was assessed using patient-reported responses to pain-specific questions from the Haem-A-QoL/Haemo-QoL-SF and the pain/discomfort dimension of the EQ-5D-5L. Responses were recorded at baseline and at regular intervals for up to 78 weeks following treatment initiation. Additional analyses evaluated the population with target joints at baseline, and the overall population stratified by age, factor (F)VIII inhibitor status and prior treatment.

Results: At the data cut-off, 504 PwHA had been treated across the four studies; 464 and 470 completed the Haem-A-QoL/Haemo-QoL-SF and the EQ-5D-5L, respectively. Improvements in pain-related QoL were observed by Week 13 of emicizumab prophylaxis and maintained through Week 78. In the overall population, responses of 'never/rarely' for 'my swellings hurt' and 'pain in joints' increased from 37.0% and 30.0% at baseline to 84.0% and 61.0% by Week 13, suggesting reductions in acute and chronic pain, respectively. Similar improvements were seen in the target joint population, and across all strata. Greater improvements were observed in younger versus older PwHA.

Conclusion: Pain-related QoL improved with emicizumab prophylaxis regardless of target joints, age, FVIII inhibitor status or prior treatment. Haemophilia-specific assessments are needed to accurately capture and characterize pain in PwHA.

References

Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi R . Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023; 10(3):e168-e177. DOI: 10.1016/S2352-3026(22)00377-5. View

Kitazawa T, Esaki K, Tachibana T, Ishii S, Soeda T, Muto A . Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017; 117(7):1348-1357. PMC: 6292136. DOI: 10.1160/TH17-01-0030. View

Oldenburg J . Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015; 125(13):2038-44. DOI: 10.1182/blood-2015-01-528414. View

Barg A, Budnik I, Avishai E, Brutman-Barazani T, Bashari D, Misgav M . Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring. Haemophilia. 2021; 27(3):383-391. DOI: 10.1111/hae.14318. View

Hassan E, Motwani J . Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review. Pediatr Hematol Oncol. 2022; 39(5):418-426. DOI: 10.1080/08880018.2021.2004269. View

Callaghan M, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M . Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242. PMC: 8065240. DOI: 10.1182/blood.2020009217. View

Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso M . Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018; 379(9):811-822. DOI: 10.1056/NEJMoa1803550. View

Levy-Mendelovich S, Brutman-Barazani T, Budnik I, Avishai E, Barg A, Levy T . Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab. J Clin Med. 2021; 10(19). PMC: 8509656. DOI: 10.3390/jcm10194303. View

duTreil S . Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med. 2014; 5:115-22. PMC: 4114907. DOI: 10.2147/JBM.S63265. View

10.

Pasi J, Hermans C, Hakimi Z, Nazir J, Aballea S, Ezzalfani M . Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study. Ther Adv Hematol. 2022; 13:20406207221079482. PMC: 8882950. DOI: 10.1177/20406207221079482. View

11.

Warren B, Thornhill D, Stein J, Fadell M, Ingram J, Funk S . Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020; 4(11):2451-2459. PMC: 7284094. DOI: 10.1182/bloodadvances.2019001311. View

12.

von Mackensen S, Bullinger M . Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia. 2004; 10 Suppl 1:17-25. DOI: 10.1111/j.1355-0691.2004.00875.x. View

13.

Garcia J, Zia A . Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab. Pediatr Blood Cancer. 2021; 68(5):e28942. DOI: 10.1002/pbc.28942. View

14.

Witkop M, Neff A, Buckner T, Wang M, Batt K, Kessler C . Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017; 23(4):556-565. DOI: 10.1111/hae.13214. View

15.

Blanchette V, Key N, Ljung L, Manco-Johnson M, van den Berg H, Srivastava A . Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11):1935-9. DOI: 10.1111/jth.12672. View

16.

Kempton C, Buckner T, Fridman M, Iyer N, Cooper D . Factors associated with pain severity, pain interference, and perception of functional abilities independent of joint status in US adults with hemophilia: Multivariable analysis of the Pain, Functional Impairment, and Quality of Life (P-FiQ) study. Eur J Haematol. 2018; 100 Suppl 1:25-33. DOI: 10.1111/ejh.13025. View

17.

Yang R, Wang S, Wang X, Sun J, Chuansumrit A, Zhou J . Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5). Res Pract Thromb Haemost. 2022; 6(2):e12670. PMC: 8902287. DOI: 10.1002/rth2.12670. View

18.

Jimenez-Yuste V, Peyvandi F, Klamroth R, Castaman G, Shanmukhaiah C, Rangarajan S . Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost. 2022; 6(8):e12837. PMC: 9663319. DOI: 10.1002/rth2.12837. View

19.

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe S . WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6:1-158. DOI: 10.1111/hae.14046. View

20.

Skinner M, Negrier C, Paz-Priel I, Chebon S, Jimenez-Yuste V, Callaghan M . The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021; 27(5):854-865. PMC: 8518882. DOI: 10.1111/hae.14363. View